MedTrace Logo

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

NCT02742675 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-07-07

No results posted yet for this study

Summary

The goal of this clinical research is to learn if treatment with androgen deprivation therapy in combination with surgery or radiation therapy can prolong the progression-free survival of oligometastatic prostate cancer than androgen deprivation therapy alone. The safety of this treatment combination will also be studied.

Conditions

Interventions

DRUG

Bicalutamide

Given orally

DRUG

goserelin acetate

Given subcutaneously or as an injection

DRUG

flutamide

Given orally

DRUG

leuprolide acetate

Given subcutaneously or as an injection

DRUG

triptorelin

Given subcutaneously or as an injection

PROCEDURE

Definitive Treatment

surgery to remove prostate or radiation therapy to the prostate.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Ye Dingwei, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2021-03-31
Completion
2023-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742675 on ClinicalTrials.gov